OBJECTIVE: Diabetes mellitus has been associated with an increased risk of Alzheimer disease (AD), but how it exerts its effect remains controversial. Possible pathophysiologic mechanisms are glucose toxicity and a direct effect of insulin on amyloid metabolism. Most studies had short follow-up, and longer-term effects of diabetes on AD risk are unknown. We investigated whether fasting glucose and insulin levels and insulin resistance are associated with the risk of AD and whether this risk is constant over time. METHODS: The study was based on 3,139 participants of the Rotterdam Study, a population-based cohort study. All subjects were free from dementia, did not have a history of diabetes, and had fasting levels of glucose and insulin measured at baseline. Insulin resistance was estimated with the homeostasis model assessment. We investigated how fasting glucose, insulin, and insulin resistance are related to the risk of AD in 3 different strata according to time-to-event, using Cox proportional hazards models. RESULTS: During follow-up, 211 participants developed AD, 71 of them within 3 years of baseline. Levels of insulin and insulin resistance were associated with a higher risk of AD within 3 years of baseline. After 3 years, the risk was no longer increased. Glucose was not associated with a higher risk of AD. There was no interaction of APOE ε4 carriership and insulin metabolism on the risk of AD. CONCLUSIONS: Our findings suggest that insulin metabolism influences the clinical manifestation of AD only within 3 years.
OBJECTIVE:Diabetes mellitus has been associated with an increased risk of Alzheimer disease (AD), but how it exerts its effect remains controversial. Possible pathophysiologic mechanisms are glucose toxicity and a direct effect of insulin on amyloid metabolism. Most studies had short follow-up, and longer-term effects of diabetes on AD risk are unknown. We investigated whether fasting glucose and insulin levels and insulin resistance are associated with the risk of AD and whether this risk is constant over time. METHODS: The study was based on 3,139 participants of the Rotterdam Study, a population-based cohort study. All subjects were free from dementia, did not have a history of diabetes, and had fasting levels of glucose and insulin measured at baseline. Insulin resistance was estimated with the homeostasis model assessment. We investigated how fasting glucose, insulin, and insulin resistance are related to the risk of AD in 3 different strata according to time-to-event, using Cox proportional hazards models. RESULTS: During follow-up, 211 participants developed AD, 71 of them within 3 years of baseline. Levels of insulin and insulin resistance were associated with a higher risk of AD within 3 years of baseline. After 3 years, the risk was no longer increased. Glucose was not associated with a higher risk of AD. There was no interaction of APOE ε4 carriership and insulin metabolism on the risk of AD. CONCLUSIONS: Our findings suggest that insulin metabolism influences the clinical manifestation of AD only within 3 years.
Authors: G M Henriksen; M M Pedersen; I Nørgaard; M Blom; L Blou; O Blaabjerg; A Uldall Journal: Scand J Clin Lab Invest Date: 2004 Impact factor: 1.713
Authors: E Bonora; G Targher; M Alberiche; R C Bonadonna; F Saggiani; M B Zenere; T Monauni; M Muggeo Journal: Diabetes Care Date: 2000-01 Impact factor: 19.112
Authors: S Craft; S Asthana; G Schellenberg; L Baker; M Cherrier; A A Boyt; R N Martins; M Raskind; E Peskind; S Plymate Journal: Ann N Y Acad Sci Date: 2000-04 Impact factor: 5.691
Authors: Sjoerd M Euser; Naveed Sattar; Jacqueline C M Witteman; Eduard L E M Bollen; Eric J G Sijbrands; Albert Hofman; Ivan J Perry; Monique M B Breteler; Rudi G J Westendorp Journal: Diabetes Date: 2010-04-14 Impact factor: 9.461
Authors: Albert Hofman; Monique M B Breteler; Cornelia M van Duijn; Harry L A Janssen; Gabriel P Krestin; Ernst J Kuipers; Bruno H Ch Stricker; Henning Tiemeier; André G Uitterlinden; Johannes R Vingerling; Jacqueline C M Witteman Journal: Eur J Epidemiol Date: 2009 Impact factor: 8.082
Authors: Monica Garcia-Alloza; Julia Gregory; Kishore V Kuchibhotla; Sara Fine; Ying Wei; Cenk Ayata; Matthew P Frosch; Steven M Greenberg; Brian J Bacskai Journal: Brain Date: 2011-11-26 Impact factor: 13.501
Authors: F W Unverzagt; L A McClure; V G Wadley; N S Jenny; R C Go; M Cushman; B M Kissela; B J Kelley; R Kennedy; C S Moy; V Howard; G Howard Journal: Neurology Date: 2011-11-08 Impact factor: 9.910
Authors: Kai Long Zhong; Fang Chen; Hao Hong; Xuan Ke; Yang Ge Lv; Su Su Tang; Yu Bing Zhu Journal: Metab Brain Dis Date: 2018-04-06 Impact factor: 3.584
Authors: Tzu-Ying Chen; Mario G Ferruzzi; Qing-Li Wu; James E Simon; Stephen T Talcott; Jun Wang; Lap Ho; George Todd; Bruce Cooper; Giulio M Pasinetti; Elsa M Janle Journal: Mol Nutr Food Res Date: 2017-08-14 Impact factor: 5.914